Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial

• Status: Terminated
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and study procedures.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Canadian Critical Care Trials Group
• Collaborators: Canadian Institutes of Health Research (CIHR); Public Health Agency of Canada (PHAC); The Physicians' Services Incorporated Foundation
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Critically ill adult patients > 16 years of age admitted to an adult ICU for any reason with suspected, probable or confirmed novel swine origin influenza A/H1N1 infection

• Requiring mechanical ventilation (invasive or non-invasive)

• Receiving antiviral therapy (any medication at any dose and for any intended duration) for < 72 hours

• Clinicians must have a 'moderate', 'high' or 'moderate to high' index of suspicion for H1N1

Exclusion Criteria:

• Age < 16 years

• Do not resuscitate or re-intubate order documented on chart or anticipated withdrawal of life support

• Weight < 40 kg

• Unable to receive or unlikely to absorb enteral study drug (e.g. incomplete or complete bowel obstruction, intestinal ischemia, infarction, short bowel syndrome)

• Rosuvastatin specific exclusions:

1. Already receiving a statin (Atorvastatin, Lovastatin, Simvastatin, Pravastatin, Rosuvastatin)

2. Allergy or intolerance to statins

3. Receiving niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir or planned use of oral contraceptives or estrogen therapy during the ICU stay

4. CK exceeds 10 times ULN or ALT exceeds 8 times the ULN

• Severe chronic liver disease (Child-Pugh Score 11-15) (see Appendix 6)

• Previous enrolment in this trial

• Pregnancy or breast feeding

• At the time of enrolment, patients must not have received >72 hours of antiviral therapy